MOH's transgender healthcare ban critique: scientific angle
by Heckin’ Unicorn|
Updated on
In May 2026, Singapore's Ministry of Health (MOH) introduced restrictions to trans healthcare for those below 21 years old. There are 2 guidelines: Children | Adolescents
MOH banned puberty blockers (puberty suppression) for those below 21 years old. This amounts to effectively a complete ban on puberty blockers, since they're not needed after puberty, and puberty typically ends before 21. (Page 5)
MOH banned gender-affirming hormone therapy for those below 18 years old (page 5)
Trans youths aged 18–21 years old can only access gender-affirming medical treatment if they fulfil these requirements (pages 5 & 19):
They have parental consent
They find a "treatment review panel" that is made up of at least 4–5 medical specialists. Each medical specialist needs to perform an assessment on them, and then convene a meeting to discuss their case, and only approve gender-affirming hormone therapy if all the medical specialists agree that there are "exceptional circumstances".
MOH cited the American College of Pediatricians (ACPeds) in their medical guidelines for transgender healthcare (page 4). The ACPeds is not a real medical organisation, but rather a religious hate group that is anti-abortion. Other examples of designated hate groups include the KKK. The ACPeds has a history of "propagating damaging falsehoods about LGBT people", and have been denounced by the US National Association of Social Workers (120,000+ members) as "out of step with research-based positions".
The ACPeds' claim cited by MOH has already been debunked by experts a while back.
One of MOH's reasons for their ban on puberty blockers is that the "current evidence on the use of puberty suppression in the treatment of gender dysphoria in adolescents is largely based on observational studies and of low quality" (page 19).
It's generally considered unethical to conduct higher quality randomised controlled trials on trans healthcare for young people, mainly because existing treatment (e.g. gender-affirming hormone therapy or puberty blockers) have been proven to work well to alleviate gender dysphoria. This is the principle of clinical equipoise.
In essence, because randomised controlled trials rely on giving half of the participants a placebo and half of them the treatment, the more effective the current treatment is known to be, the more unethical it is to intentionally deprive half of the participants of treatment.
In the same vein, it also makes it increasingly unethical for a doctor to persuade their patient to undergo such trials, knowing that doing so might deprive their patient of a known treatment.
There also needs to be "honest, professional disagreement among expert clinicians" about gender-affirming treatments in order for ethics boards to approve such trials. Given that most of the disagreements about gender-affirming healthcare stem from religious arguments rather than clinical concerns, it is even more unlikely for a competent medical ethics board to approve such trials, especially on youths.
MOH knows that one reason why higher quality, randomised controlled trials don't exist is because of "ethical difficulties" (page 6).
The National University Hospital of Singapore and Khoo Teck Puat Hospital published an informational booklet on precocious puberty (when puberty starts way too early in a child). In it, the hospitals mention puberty blockers (GnRH analogue) as treatment for central precocious puberty.
A meta study of 98 studies found that the overall quality of evidence for the use of puberty blockers as treatment for central precocious puberty "ranged from very low to moderate".
Many international medical organisations publish medical guidelines for transgender healthcare. They include but are not limited to:
WPATH: World Professional Association for Transgender Health, which published their Standards of Care Version 8 (SOC8). SOC8 is one of the most internationally accepted medical guideline for trans health.
PATHSA: Professional Association for Transgender Health South Africa, which published a rapid review of gender-affirming healthcare for children and adolescents.
The Health Council of Netherlands published a review of gender-affirming healthcare for adolescents, and concluded that "hormone treatments are physically effective", and that they see "no reason, based on the limited data that are available on this subject, not to offer the treatments, especially because denying treatment can also have harmful consequences for mental health".
The medical guidelines published by the organisations above don't use hard age limits to decide whether a patient should require medical intervention. WPATH's SOC8 has a chapter dedicated to adolescents, and they specifically warn that adolescence cannot be defined exclusively by age (page S43). Instead, they stated that an individualised approach to clinical care is considered both ethical and necessary (page S45).
In an email interview with Dr. Eli Coleman, first author of SOC8, he told us that he's not aware of research that evaluates trans healthcare needs based on age requirements. "There is more evidence supporting treatment given meeting certain criteria and careful multidisciplinary assessment," he said.
On 21 Oct 2026, New Zealand's High Court ruled that their government's age-based restrictions to gender-affirming trans healthcare is unlawful and discriminatory.
